Hilde Celis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hilde Celis has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Jan A. Staessen
Department of Cardiovascular Medicine, Shanghai Key Laboratory of Hypertension, Shanghai Institute of Hypertension, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
8 shared publications L Thijs
6 shared publicationsR Fagard
6 shared publicationsP De Cort
3 shared publicationsElly Den Hond
Hilde Celis, MD, Elly Den Hond, PhD, Jan A. Staessen, MD, PhD, FAHA, Study Coordinating Center, Hypertension and Cardiovascular Rehabilitation Unit, Department of Molecular and Cardiovascular Research, University of Leuven, Leuven, Belgium
2 shared publicationsLutgarde Thijs
From Study Coordinating Centre, Hypertension and Cardiovascular Rehabilitation Unit, Department of Molecular and Cardiovascular Research, University of Leuven, Leuven, Belgium; Department of General Practice, University of Leuven, Leuven, Belgium; Department of Cardiology, University of Ghent, Ghent, Belgium; Blood Pressure Unit, Beaumont Hospital, Dublin, Ireland
2 shared publications
Latest Publications
- Open Access
- 1 February 2005
- Published by Marshfield Clinic Research Institute in Clinical Medicine & Research
- Vol. 3 (1) , 19-26
Self-Measurement of Blood Pressure at Home in the Management of Hypertension
To be suitable for the management of hypertension, self-measurement of blood pressure (BP) at home should follow international recommendations. The use of accurate and validated measuring devices is an important prerequisite. Upper arm BP monitors are the first choice, while wrist and finger devices cannot be recommended. Measurements should, preferentially, be downloaded from the memory of a device or printed. Reference values have been proposed, but were mostly based on cross-sectional observations and have not yet been widely validated by prospective outcome studies. Currently, levels of home BP of <135 mm Hg systolic and 85 mm Hg diastolic are usually considered normal. Home BP measurement is sometimes recommended as an alternative to ambulatory BP monitoring to diagnose white-coat hypertension. However, home BP measurement cannot replace ambulatory BP monitoring in the diagnosis of hypertension (white-coat), but both techniques have complementary roles. The appropriateness of home BP measurement to guide antihypertensive treatment has only been tested in one large-scale randomized trial: the THOP (Treatment of Hypertension Based on Home or Office Blood Pressure) trial. The THOP trial showed that antihypertensive treatment based on home instead of office BP led to less intensive drug treatment, but also to less BP control with no differences in general wellbeing and left ventricular mass. Home BP monitoring also contributed to the identification of patients with white-coat hypertension. On balance, most evidence supports the view that office BP measurement remains the key in the diagnosis and treatment of hypertension. Treatment can be started without confirmation of elevated office BP in patients with high office BP and target organ damage, or a high cardiovascular risk profile. In patients with raised office BP but without target organ damage (white-coat hypertension), or with normal office BP but unexplained target organ damage (masked hypertension), ambulatory or home BP monitoring or both must be used to confirm the diagnosis. Few longitudinal studies have addressed the long-term prognostic meaning of home BP measurement. Until more prospective data become available, management of hypertension exclusively based on self-measurement of BP at home cannot be recommended.
- 1 February 2005
- Published by Marshfield Clinic Research Institute in Clinical Medicine & Research
- Vol. 3 (1) , 19-26
Open AccessSelf-Measurement of Blood Pressure at Home in the Management of Hypertension
To be suitable for the management of hypertension, self-measurement of blood pressure (BP) at home should follow international recommendations. The use of accurate and validated measuring devices is an important prerequisite. Upper arm BP monitors are the first choice, while wrist and finger devices cannot be recommended. Measurements should, preferentially, be downloaded from the memory of a device or printed. Reference values have been proposed, but were mostly based on cross-sectional observations and have not yet been widely validated by prospective outcome studies. Currently, levels of home BP of <135 mm Hg systolic and 85 mm Hg diastolic are usually considered normal. Home BP measurement is sometimes recommended as an alternative to ambulatory BP monitoring to diagnose white-coat hypertension. However, home BP measurement cannot replace ambulatory BP monitoring in the diagnosis of hypertension (white-coat), but both techniques have complementary roles. The appropriateness of home BP measurement to guide antihypertensive treatment has only been tested in one large-scale randomized trial: the THOP (Treatment of Hypertension Based on Home or Office Blood Pressure) trial. The THOP trial showed that antihypertensive treatment based on home instead of office BP led to less intensive drug treatment, but also to less BP control with no differences in general wellbeing and left ventricular mass. Home BP monitoring also contributed to the identification of patients with white-coat hypertension. On balance, most evidence supports the view that office BP measurement remains the key in the diagnosis and treatment of hypertension. Treatment can be started without confirmation of elevated office BP in patients with high office BP and target organ damage, or a high cardiovascular risk profile. In patients with raised office BP but without target organ damage (white-coat hypertension), or with normal office BP but unexplained target organ damage (masked hypertension), ambulatory or home BP monitoring or both must be used to confirm the diagnosis. Few longitudinal studies have addressed the long-term prognostic meaning of home BP measurement. Until more prospective data become available, management of hypertension exclusively based on self-measurement of BP at home cannot be recommended.
- 1 January 2002
- Published by Taylor & Francis in Blood Pressure
- Vol. 11 (6) , 352-356
Cardiovascular Risk In White-coat and Sustained Hypertensive Patients
We compared cardiovascular outcome between patients with white-coat and sustained hypertension who had previously participated in the Ambulatory Blood Pressure Monitoring and Treatment of Hypertension (APTH) trial. Baseline characteristics, including office and ambulatory blood pressure (BP), were measured during the 2-month run-in period of the APTH trial. During follow-up, information on the occurrence of major cardiovascular events (death, myocardial infarction, stroke and heart failure), achieved office BP and treatment status was obtained. At entry, 326 patients had sustained hypertension (daytime ambulatory BP S 140 mmHg systolic and/or S 90 mmHg diastolic) and 93 had daytime ambulatory BP below these limits and were classified as white-coat hypertensives. During 2088 patientyears of follow-up (median follow-up 5.3 years), all major cardiovascular events ( n = 22) occurred in the patients with sustained hypertension (rate 12.7 per 1000 patient-years, p = 0.02 for between-group difference). Furthermore, multiple Cox regression confirmed that after adjustment for important covariables, daytime ambulatory BP - but not office BP at entry - significantly and independently predicted cardiovascular outcome. After additional adjustment for office BP, daytime ambulatory BP still predicted the occurrence of major cardiovascular events. Although white-coat hypertension was less frequently associated with antihypertensive drug treatment during follow-up, it carried a significantly better prognosis than sustained hypertension.
- 1 January 2002
- Published by Taylor & Francis in Blood Pressure
- Vol. 11 (6) , 352-356
Cardiovascular Risk In White-coat and Sustained Hypertensive Patients
We compared cardiovascular outcome between patients with white-coat and sustained hypertension who had previously participated in the Ambulatory Blood Pressure Monitoring and Treatment of Hypertension (APTH) trial. Baseline characteristics, including office and ambulatory blood pressure (BP), were measured during the 2-month run-in period of the APTH trial. During follow-up, information on the occurrence of major cardiovascular events (death, myocardial infarction, stroke and heart failure), achieved office BP and treatment status was obtained. At entry, 326 patients had sustained hypertension (daytime ambulatory BP S 140 mmHg systolic and/or S 90 mmHg diastolic) and 93 had daytime ambulatory BP below these limits and were classified as white-coat hypertensives. During 2088 patientyears of follow-up (median follow-up 5.3 years), all major cardiovascular events ( n = 22) occurred in the patients with sustained hypertension (rate 12.7 per 1000 patient-years, p = 0.02 for between-group difference). Furthermore, multiple Cox regression confirmed that after adjustment for important covariables, daytime ambulatory BP - but not office BP at entry - significantly and independently predicted cardiovascular outcome. After additional adjustment for office BP, daytime ambulatory BP still predicted the occurrence of major cardiovascular events. Although white-coat hypertension was less frequently associated with antihypertensive drug treatment during follow-up, it carried a significantly better prognosis than sustained hypertension.
- 1 December 2001
- Vol. 91 (12) , 1060-8
Dihydropyridine calcium-channel blockers for antihypertensive treatment in older patients--evidence from the Systolic Hypertension in Europe Trial.
The Syst-Eur study investigated whether active antihypertensive treatment could reduce cardiovascular complications in elderly patients with isolated systolic hypertension. Randomised, placebo-controlled, double-blind outcome trial. Hypertension clinics or general practitioners' surgeries in 198 centres in 23 Western and Eastern European countries. Patients aged > or = 60 years with sitting systolic blood pressure (BP) 160-219 mmHg and sitting diastolic BP < 95 mmHg during run-in phase. Four thousand, six hundred and ninety-five patients were randomly assigned to active treatment (N = 2,398), i.e. nitrendipine, with the possible addition of enalapril and hydrochlorothiazide, or to matching placebos (N = 2,297). In the intention-to-treat analysis, the between-group difference in blood pressure (BP) amounted to 10.1/4.5 mmHg (P < 0.001). Active treatment reduced the incidence of fatal and non-fatal stroke (primary endpoint) by 42% (P = 0.003). On active treatment all cardiac endpoints decreased by 26% (P = 0.03) and all cardiovascular endpoints by 31% (P < 0.001). Cardiovascular mortality was slightly lower on active treatment (-27%, P = 0.07), but all-cause mortality was not influenced (-14%, P = 0.22). For total (P = 0.009) and cardiovascular mortality (P = 0.09), the benefit of antihypertensive treatment weakened with advancing age, and for total mortality it decreased with lower systolic BP at entry (P = 0.05). The benefits of active treatment were not independently related to sex or to the presence of cardiovascular complications at entry. The antihypertensive regimen was more effective in patients with diabetes than in those without diabetes at entry. Further analyses also suggested benefit in patients who were taking nitrendipine as the sole therapy. The per-protocol analysis largely confirmed the intention-to-treat results. Active treatment reduced all strokes by 44% (P = 0.004), all cardiac endpoints by 26% (P = 0.05) and all cardiovascular endpoints by 32% (P < 0.001). Total mortality was reduced by 26% (P = 0.05), but a similar reduction in cardiovascular mortality did not reach statistical significance in this analysis. Compared with placebo, active treatment also reduced the incidence of dementia by 50%. Stepwise antihypertensive drug treatment, starting with the dihydropiridine calcium-channel blocker nitrendipine, improves prognosis in elderly patients with isolated systolic hypertension.
- 1 December 2001
- Vol. 91 (12) , 1060-8
Dihydropyridine calcium-channel blockers for antihypertensive treatment in older patients--evidence from the Systolic Hypertension in Europe Trial.
The Syst-Eur study investigated whether active antihypertensive treatment could reduce cardiovascular complications in elderly patients with isolated systolic hypertension. Randomised, placebo-controlled, double-blind outcome trial. Hypertension clinics or general practitioners' surgeries in 198 centres in 23 Western and Eastern European countries. Patients aged > or = 60 years with sitting systolic blood pressure (BP) 160-219 mmHg and sitting diastolic BP < 95 mmHg during run-in phase. Four thousand, six hundred and ninety-five patients were randomly assigned to active treatment (N = 2,398), i.e. nitrendipine, with the possible addition of enalapril and hydrochlorothiazide, or to matching placebos (N = 2,297). In the intention-to-treat analysis, the between-group difference in blood pressure (BP) amounted to 10.1/4.5 mmHg (P < 0.001). Active treatment reduced the incidence of fatal and non-fatal stroke (primary endpoint) by 42% (P = 0.003). On active treatment all cardiac endpoints decreased by 26% (P = 0.03) and all cardiovascular endpoints by 31% (P < 0.001). Cardiovascular mortality was slightly lower on active treatment (-27%, P = 0.07), but all-cause mortality was not influenced (-14%, P = 0.22). For total (P = 0.009) and cardiovascular mortality (P = 0.09), the benefit of antihypertensive treatment weakened with advancing age, and for total mortality it decreased with lower systolic BP at entry (P = 0.05). The benefits of active treatment were not independently related to sex or to the presence of cardiovascular complications at entry. The antihypertensive regimen was more effective in patients with diabetes than in those without diabetes at entry. Further analyses also suggested benefit in patients who were taking nitrendipine as the sole therapy. The per-protocol analysis largely confirmed the intention-to-treat results. Active treatment reduced all strokes by 44% (P = 0.004), all cardiac endpoints by 26% (P = 0.05) and all cardiovascular endpoints by 32% (P < 0.001). Total mortality was reduced by 26% (P = 0.05), but a similar reduction in cardiovascular mortality did not reach statistical significance in this analysis. Compared with placebo, active treatment also reduced the incidence of dementia by 50%. Stepwise antihypertensive drug treatment, starting with the dihydropiridine calcium-channel blocker nitrendipine, improves prognosis in elderly patients with isolated systolic hypertension.
- 1 November 2001
- Published by Wolters Kluwer Health in Current Opinion in Cardiology
- Vol. 16 (6) , 342-348
Risk and benefit of treatment of isolated systolic hypertension in the elderly: evidence from the Systolic Hypertension in Europe Trial
The Syst-Eur trial investigated whether active treatment starting with the dihydropyridine calcium channel blocker (CCB) nitrendipine, could reduce the cardiovascular complications of isolated systolic hypertension (ISH) in the elderly. The intention-to-treat analysis showed that active treatment improved outcome. The per-protocol analysis largely confirmed these results. The effect of treatment on total and cardiovascular mortality might be attenuated in very old patients. Further analysis also suggested benefit in those patients who remained on nitrendipine monotherapy. Active treatment was more beneficial in patients with diabetes as compared with those without diabetes at entry and reduced the incidence of dementia by 50%. Analyses of data from the Ambulatory Blood Pressure Monitoring (ABPM) Side Project suggested that most of the benefit of treatment was seen in patients with a daytime systolic BP ≥ 160 mm Hg. Finally, a meta-analysis partly based on Syst-Eur data showed that in older hypertensive patients pulse pressure and not mean pressure is the major determinant of cardiovascular risk.
- 1 November 2001
- Published by Wolters Kluwer Health in Current Opinion in Cardiology
- Vol. 16 (6) , 342-348
Risk and benefit of treatment of isolated systolic hypertension in the elderly: evidence from the Systolic Hypertension in Europe Trial
The Syst-Eur trial investigated whether active treatment starting with the dihydropyridine calcium channel blocker (CCB) nitrendipine, could reduce the cardiovascular complications of isolated systolic hypertension (ISH) in the elderly. The intention-to-treat analysis showed that active treatment improved outcome. The per-protocol analysis largely confirmed these results. The effect of treatment on total and cardiovascular mortality might be attenuated in very old patients. Further analysis also suggested benefit in those patients who remained on nitrendipine monotherapy. Active treatment was more beneficial in patients with diabetes as compared with those without diabetes at entry and reduced the incidence of dementia by 50%. Analyses of data from the Ambulatory Blood Pressure Monitoring (ABPM) Side Project suggested that most of the benefit of treatment was seen in patients with a daytime systolic BP ≥ 160 mm Hg. Finally, a meta-analysis partly based on Syst-Eur data showed that in older hypertensive patients pulse pressure and not mean pressure is the major determinant of cardiovascular risk.
- 1 September 2001
- Published by Springer Nature in Journal of Human Hypertension
- Vol. 15 (9) , 613-618
Interaction between nonsteroidal anti-inflammatory drug intake and calcium-channel blocker-based antihypertensive treatment in the Syst-Eur trial
OBJECTIVE: To assess the relationship between chronic intake of nonsteroidal anti-inflammatory drugs (NSAID) and outcome, in particular (gastrointestinal) bleeding and to investigate whether the effect of chronic NSAID intake was similar in untreated and treated elderly hypertensives. METHODS: Eligible patients (> or = 60 years, with systolic blood pressure 160-219 mm Hg and diastolic blood pressure < 95 mm Hg) were randomised to active treatment or placebo. Active treatment consisted of nitrendipine, with the possible addition of enalapril, hydrochlorothiazide, or both, titrated or combined to reduce the sitting systolic blood pressure by at least 20 mm Hg to below 150 mm Hg. Patients never taking NSAIDs (n = 2882) were compared with patients on chronic NSAID intake (n = 861), defined as reporting NSAID intake on at least 50% of the patient forms. RESULTS: There was a tendency towards lower mortality (relative hazard rate (95% confidence interval (CI), 0.77 (0.56-1.06)) and higher incidence of bleeding (1.13 (0.63-2.05) with chronic NSAID intake. Although there was no significant interaction between calcium-channel blocker (CCB)-based treatment and chronic NSAID intake for any of the end points, chronic NSAID intake tended to be associated with a lower incidence of bleeding on active treatment as compared to placebo (P-value of the interaction term = 0.07). CONCLUSION: The effect of chronic NSAID intake on outcome was similar in patients on active treatment based on a dihydropyridine CCB or on placebo. However, chronic NSAID intake might have a less deleterious effect on bleeding on active treatment as compared to placebo.status: publishe
- 1 September 2001
- Published by Springer Nature in Journal of Human Hypertension
- Vol. 15 (9) , 613-618
Interaction between nonsteroidal anti-inflammatory drug intake and calcium-channel blocker-based antihypertensive treatment in the Syst-Eur trial
OBJECTIVE: To assess the relationship between chronic intake of nonsteroidal anti-inflammatory drugs (NSAID) and outcome, in particular (gastrointestinal) bleeding and to investigate whether the effect of chronic NSAID intake was similar in untreated and treated elderly hypertensives. METHODS: Eligible patients (> or = 60 years, with systolic blood pressure 160-219 mm Hg and diastolic blood pressure < 95 mm Hg) were randomised to active treatment or placebo. Active treatment consisted of nitrendipine, with the possible addition of enalapril, hydrochlorothiazide, or both, titrated or combined to reduce the sitting systolic blood pressure by at least 20 mm Hg to below 150 mm Hg. Patients never taking NSAIDs (n = 2882) were compared with patients on chronic NSAID intake (n = 861), defined as reporting NSAID intake on at least 50% of the patient forms. RESULTS: There was a tendency towards lower mortality (relative hazard rate (95% confidence interval (CI), 0.77 (0.56-1.06)) and higher incidence of bleeding (1.13 (0.63-2.05) with chronic NSAID intake. Although there was no significant interaction between calcium-channel blocker (CCB)-based treatment and chronic NSAID intake for any of the end points, chronic NSAID intake tended to be associated with a lower incidence of bleeding on active treatment as compared to placebo (P-value of the interaction term = 0.07). CONCLUSION: The effect of chronic NSAID intake on outcome was similar in patients on active treatment based on a dihydropyridine CCB or on placebo. However, chronic NSAID intake might have a less deleterious effect on bleeding on active treatment as compared to placebo.status: publishe
- Open Access
- 1 April 1999
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 12 (4) , 145-145A
Systolic hypertension in Europe (Syst-Eur) trial phase 2: objectives, protocol, and initial progress.
J. Gasowski, Systolic Hypertension in Europe Investigators, J.A. Staessen, Systolic Hypertension in Europe Investigators, H. Celis, Systolic Hypertension in Eur
- 1 April 1999
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 12 (4) , 145-145A
Open AccessSystolic hypertension in Europe (Syst-Eur) trial phase 2: objectives, protocol, and initial progress.
J. Gasowski, Systolic Hypertension in Europe Investigators, J.A. Staessen, Systolic Hypertension in Europe Investigators, H. Celis, Systolic Hypertension in Eur
- 1 April 1999
- Vol. 4 (2) , 77-86
The international database of self-recorded blood pressures in normotensive and untreated hypertensive subjects.
To pool data from individual subjects in an attempt to determine an operational threshold for making clinical decisions based on the self-recorded blood pressure (SRBP) and to examine how many hypertensive subjects, diagnosed by conventional blood pressure (CBP) measurement, would have a self-recorded blood pressure within the normotensive range if the proposed thresholds were applied. Thirteen research groups studied 4668 untreated subjects. In total 2401 subjects were normotensive, 494 were borderline hypertensive and 1773 were definitely hypertensive. Hypertension had been diagnosed from the mean of 1-6 (median 3) CBP measurements obtained during 1-3 (median 1) visits. The reference values for SRBP measurements determined from the 95th percentiles of the distributions for normotensive subjects were 137 mmHg systolic and 85 mmHg diastolic. Of the subjects with systolic hypertension, 16% had systolic SRBP </= 137 mmHg. Similarly, 25% of those with diastolic hypertension had diastolic SRBP </= 85 mmHg. The probability that hypertensive subjects had SRBP below these thresholds was 34% (diastolic) to 62% (systolic) greater for women than it was for men, was 2-3 times greater if fewer than three CBP measurements had been averaged for establishing the diagnosis of hypertension, and increased by 50% (diastolic) to 126% (systolic) when SRBP had been measured on more than 3 days. In contrast, for each 10 mmHg increment in systolic CBP, this probability decreased by 35% for systolic SRBP and by 11% for diastolic SRBP; for each 5 mmHg increment in diastolic CBP it decreased by 36% for diastolic SRBP. In addition, for systolic blood pressure, the probability decreased by 31% for each 10-year increment in age. Until the relationship between SRBP and the incidence of cardiovascular morbidity and mortality has been clarified further by prospective studies, a mean self-recorded blood pressure above 137 mmHg systolic or 85 mmHg diastolic may be considered hypertensive. Among the hypertensive patients 16-31% had SRBP below these thresholds, but this proportion decreased if the hypertensive subjects had higher CBP.
- 1 April 1999
- Vol. 4 (2) , 77-86
The international database of self-recorded blood pressures in normotensive and untreated hypertensive subjects.
To pool data from individual subjects in an attempt to determine an operational threshold for making clinical decisions based on the self-recorded blood pressure (SRBP) and to examine how many hypertensive subjects, diagnosed by conventional blood pressure (CBP) measurement, would have a self-recorded blood pressure within the normotensive range if the proposed thresholds were applied. Thirteen research groups studied 4668 untreated subjects. In total 2401 subjects were normotensive, 494 were borderline hypertensive and 1773 were definitely hypertensive. Hypertension had been diagnosed from the mean of 1-6 (median 3) CBP measurements obtained during 1-3 (median 1) visits. The reference values for SRBP measurements determined from the 95th percentiles of the distributions for normotensive subjects were 137 mmHg systolic and 85 mmHg diastolic. Of the subjects with systolic hypertension, 16% had systolic SRBP </= 137 mmHg. Similarly, 25% of those with diastolic hypertension had diastolic SRBP </= 85 mmHg. The probability that hypertensive subjects had SRBP below these thresholds was 34% (diastolic) to 62% (systolic) greater for women than it was for men, was 2-3 times greater if fewer than three CBP measurements had been averaged for establishing the diagnosis of hypertension, and increased by 50% (diastolic) to 126% (systolic) when SRBP had been measured on more than 3 days. In contrast, for each 10 mmHg increment in systolic CBP, this probability decreased by 35% for systolic SRBP and by 11% for diastolic SRBP; for each 5 mmHg increment in diastolic CBP it decreased by 36% for diastolic SRBP. In addition, for systolic blood pressure, the probability decreased by 31% for each 10-year increment in age. Until the relationship between SRBP and the incidence of cardiovascular morbidity and mortality has been clarified further by prospective studies, a mean self-recorded blood pressure above 137 mmHg systolic or 85 mmHg diastolic may be considered hypertensive. Among the hypertensive patients 16-31% had SRBP below these thresholds, but this proportion decreased if the hypertensive subjects had higher CBP.
- 1 October 1997
- Vol. 278 (13) , 1065-72
Antihypertensive treatment based on conventional or ambulatory blood pressure measurement. A randomized controlled trial. Ambulatory Blood Pressure Monitoring and Treatment of Hypertension Investigators.
Ambulatory blood pressure (ABP) monitoring is used increasingly in clinical practice, but how it affects treatment of blood pressure has not been determined. To compare conventional blood pressure (CBP) measurement and ABP measurement in the management of hypertensive patients. Multicenter, randomized, parallel-group trial. Family practices and outpatient clinics at regional and university hospitals. A total of 419 patients (> or =18 years), whose untreated diastolic blood pressure (DBP) on CBP measurement averaged 95 mm Hg or higher, randomized to CBP or ABP arms. Antihypertensive drug treatment was adjusted in a stepwise fashion based on either the average daytime (from 10 AM to 8 PM) ambulatory DBP (n=213) or the average of 3 sitting DBP readings (n=206). If the DBP guiding treatment was above (>89 mm Hg), at (80-89 mm Hg), or below (<80 mm Hg) target, 1 physician blinded to the patients' randomization intensified antihypertensive treatment, left it unchanged, or reduced it, respectively. The CBP and ABP levels, intensity of drug treatment, electrocardiographic and echocardiographic left ventricular mass, symptoms reported by questionnaire, and cost. At the end of the study (median follow-up, 182 days; 5th to 95th percentile interval, 85-258 days), more ABP than CBP patients had stopped antihypertensive drug treatment (26.3% vs 7.3%; P<.001), and fewer ABP patients had progressed to sustained multiple-drug treatment (27.2% vs 42.7%; P<.001). The final CBP and 24-hour ABP averaged 144.1/89.9 mm Hg and 129.4/79.5 mm Hg in the ABP group and 140.3/89.6 mm Hg and 128.0/79.1 mm Hg in the CBP group. Left ventricular mass and reported symptoms were similar in the 2 groups. The potential savings in the ABP group in terms of less intensive drug treatment and fewer physician visits were offset by the costs of ABP monitoring. Adjustment of antihypertensive treatment based on ABP monitoring instead of CBP measurement led to less intensive drug treatment with preservation of blood pressure control, general well-being, and inhibition of left ventricular enlargement but did not reduce the overall costs of antihypertensive treatment.
- 1 October 1997
- Vol. 278 (13) , 1065-72
Antihypertensive treatment based on conventional or ambulatory blood pressure measurement. A randomized controlled trial. Ambulatory Blood Pressure Monitoring and Treatment of Hypertension Investigators.
Ambulatory blood pressure (ABP) monitoring is used increasingly in clinical practice, but how it affects treatment of blood pressure has not been determined. To compare conventional blood pressure (CBP) measurement and ABP measurement in the management of hypertensive patients. Multicenter, randomized, parallel-group trial. Family practices and outpatient clinics at regional and university hospitals. A total of 419 patients (> or =18 years), whose untreated diastolic blood pressure (DBP) on CBP measurement averaged 95 mm Hg or higher, randomized to CBP or ABP arms. Antihypertensive drug treatment was adjusted in a stepwise fashion based on either the average daytime (from 10 AM to 8 PM) ambulatory DBP (n=213) or the average of 3 sitting DBP readings (n=206). If the DBP guiding treatment was above (>89 mm Hg), at (80-89 mm Hg), or below (<80 mm Hg) target, 1 physician blinded to the patients' randomization intensified antihypertensive treatment, left it unchanged, or reduced it, respectively. The CBP and ABP levels, intensity of drug treatment, electrocardiographic and echocardiographic left ventricular mass, symptoms reported by questionnaire, and cost. At the end of the study (median follow-up, 182 days; 5th to 95th percentile interval, 85-258 days), more ABP than CBP patients had stopped antihypertensive drug treatment (26.3% vs 7.3%; P<.001), and fewer ABP patients had progressed to sustained multiple-drug treatment (27.2% vs 42.7%; P<.001). The final CBP and 24-hour ABP averaged 144.1/89.9 mm Hg and 129.4/79.5 mm Hg in the ABP group and 140.3/89.6 mm Hg and 128.0/79.1 mm Hg in the CBP group. Left ventricular mass and reported symptoms were similar in the 2 groups. The potential savings in the ABP group in terms of less intensive drug treatment and fewer physician visits were offset by the costs of ABP monitoring. Adjustment of antihypertensive treatment based on ABP monitoring instead of CBP measurement led to less intensive drug treatment with preservation of blood pressure control, general well-being, and inhibition of left ventricular enlargement but did not reduce the overall costs of antihypertensive treatment.
- 1 April 1996
- Vol. 13 (2) , 138-43
Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst-Eur experience in general practice. The Syst-Eur Investigators.
This interim report from the Syst-Eur trial investigated the level of blood pressure control achieved during the double-blind period in patients followed in general practices. In the Syst-Eur trial elderly patients (60 years or older) with isolated systolic hypertension were randomized to either active or placebo treatment. Active treatment consisted of nitrendipine combined with enalapril and/or hydrochlorothiazide to reduce systolic pressure to < 150 mmHg and by > or = 20 mmHg. Matching placebos were used in the control group. This analysis was restricted to patients of general practitioners who had been followed for at least 12 months. The placebo (N = 204) and active treatment (N = 217) groups had similar characteristics at randomization. At one year, the difference in sitting pressure between the two treatment groups was 10 mmHg systolic and 4 mmHg diastolic. Fewer patients remained on monotherapy in the placebo than in the active treatment group and on placebo the second and third line medications were started earlier. Nitrendipine tablets were discontinued in 10 patients on placebo and in 21 patients assigned to active treatment (P < 0.001 for all comparisons). A significant blood pressure reduction can be achieved and maintained in older patients with isolated systolic hypertension followed by general practitioners. Whether this blood pressure reduction results in a clinically meaningful decrease of cardiovascular complications is under investigation.
- 1 April 1996
- Vol. 13 (2) , 138-43
Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst-Eur experience in general practice. The Syst-Eur Investigators.
This interim report from the Syst-Eur trial investigated the level of blood pressure control achieved during the double-blind period in patients followed in general practices. In the Syst-Eur trial elderly patients (60 years or older) with isolated systolic hypertension were randomized to either active or placebo treatment. Active treatment consisted of nitrendipine combined with enalapril and/or hydrochlorothiazide to reduce systolic pressure to < 150 mmHg and by > or = 20 mmHg. Matching placebos were used in the control group. This analysis was restricted to patients of general practitioners who had been followed for at least 12 months. The placebo (N = 204) and active treatment (N = 217) groups had similar characteristics at randomization. At one year, the difference in sitting pressure between the two treatment groups was 10 mmHg systolic and 4 mmHg diastolic. Fewer patients remained on monotherapy in the placebo than in the active treatment group and on placebo the second and third line medications were started earlier. Nitrendipine tablets were discontinued in 10 patients on placebo and in 21 patients assigned to active treatment (P < 0.001 for all comparisons). A significant blood pressure reduction can be achieved and maintained in older patients with isolated systolic hypertension followed by general practitioners. Whether this blood pressure reduction results in a clinically meaningful decrease of cardiovascular complications is under investigation.